We are live on
!
Find out more
BI
BVF Inc Portfolio holdings
AUM
$3.91B
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter
Est. Return
+37.89%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$3.91B
AUM Growth
+$772M
(+25%)
Cap. Flow
-$38.9M
Cap. Flow
% of AUM
-0.99%
Top 10 Holdings %
Top 10 Hldgs %
65.59%
Holding
46
New
5
Increased
6
Reduced
9
Closed
2
Avg Time Held
12.8
quarters
Top 10 Avg Time Held
6.3
quarters
Top 20 Avg Time Held
8.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xoma
XOMA
|
+$203M |
| 2 |
Q32 Bio
QTTB
|
+$19.6M |
| 3 |
Sagimet Biosciences
SGMT
|
+$17M |
| 4 |
Revolution Medicines
RVMD
|
+$15.8M |
| 5 |
Absci
ABSI
|
+$13.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$140M |
| 2 |
Mirum Pharmaceuticals
MIRM
|
+$53.1M |
| 3 |
Compass Therapeutics
CMPX
|
+$41.1M |
| 4 |
Palvella Therapeutics
PVLA
|
+$35M |
| 5 |
Septerna Inc
SEPN
|
+$32.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.86% |
| 2 | Financials | 0.14% |
| 3 | Miscellaneous | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Revolution Medicines
RVMD
$40.4B
| $555M | 14.2% |
2,965,160
+108,378
| +4% | +$15.8M |
2020 Q1
25 quarters
|
|
|
2
Kymera Therapeutics
KYMR
$8.87B
| $444M | 11.35% |
3,872,052
-1,630,658
| -30% | -$140M |
2020 Q3
23 quarters
|
|
|
3
DELISTED
Xoma
XOMA
| $323M | 8.25% |
7,593,303
+5,003,000
| +193% | +$203M |
2016 Q4
38 quarters
|
|
4
MoonLake Immunotherapeutics
MLTX
$886M
| $312M | 7.97% |
16,001,284
| – | – |
2022 Q2
16 quarters
|
|
5
GH Research
GHRS
$1.29B
| $233M | 5.95% |
8,650,158
| – | – |
2021 Q2
20 quarters
|
|
6
Structure Therapeutics
GPCR
$1.59B
| $181M | 4.62% |
3,366,823
-92,535
| -3% | -$4.09M |
2023 Q1
13 quarters
|
|
7
Nektar Therapeutics
NKTR
$1.29B
| $167M | 4.27% |
2,391,075
-168,520
| -7% | -$12.3M |
2025 Q3
3 quarters
|
|
|
8
Mirum Pharmaceuticals
MIRM
$5.17B
| $124M | 3.16% |
1,056,027
-528,700
| -33% | -$53.1M |
2023 Q3
11 quarters
|
|
9
Xencor
XNCR
$1.75B
| $115M | 2.94% |
7,133,720
| – | – |
2024 Q3
7 quarters
|
|
10
Alkermes
ALKS
$6.67B
| $113M | 2.89% |
2,154,704
+154,704
| +8% | +$6.04M |
2026 Q1
1 quarter
|
|
11
Monte Rosa Therapeutics
GLUE
$844M
| $108M | 2.76% |
4,460,886
| – | – |
2024 Q4
6 quarters
|
|
12
Cullinan Oncology
CGEM
$907M
| $105M | 2.68% |
5,750,683
| – | – |
2021 Q1
21 quarters
|
|
|
13
Palvella Therapeutics
PVLA
$1.85B
| $103M | 2.63% |
672,789
-288,200
| -30% | -$35M |
2016 Q2
40 quarters
|
|
14
Zymeworks
ZYME
$1.8B
| $95.4M | 2.44% |
3,649,142
-85,000
| -2% | -$2.16M |
2022 Q4
14 quarters
|
|
15
Kura Oncology
KURA
$874M
| $92.7M | 2.37% |
8,445,769
| – | – |
2017 Q3
35 quarters
|
|
16
Disc Medicine
IRON
$2.17B
| $84.4M | 2.16% |
1,153,612
-118,700
| -9% | -$8.16M |
2025 Q4
2 quarters
|
|
17
Stoke Therapeutics
STOK
$1.45B
| $83.4M | 2.13% |
2,547,557
| – | – |
2025 Q3
3 quarters
|
|
18
Olema Pharmaceuticals
OLMA
$614M
| $66.3M | 1.69% |
5,295,893
| – | – |
2020 Q4
22 quarters
|
|
19
Annexon
ANNX
$726M
| $49.7M | 1.27% |
8,698,173
| – | – |
2023 Q4
10 quarters
|
|
20
Crescent Biopharma
CBIO
$480M
| $49.5M | 1.27% |
2,748,763
| – | – |
2019 Q3
27 quarters
|
|
21
AC Immune
ACIU
$239M
| $47.2M | 1.21% |
19,822,436
| – | – |
2018 Q3
31 quarters
|
|
22
Tyra Biosciences
TYRA
$1.28B
| $47.1M | 1.21% |
1,476,196
-500,000
| -25% | -$16.5M |
2021 Q3
19 quarters
|
|
23
Sutro Biopharma
STRO
$183M
| $41.6M | 1.06% |
1,251,788
| – | – |
2026 Q1
1 quarter
|
|
24
Immunocore
IMCR
$1.43B
| $41.1M | 1.05% |
1,294,463
| – | – |
2025 Q2
4 quarters
|
|
25
Avalo Therapeutics
AVTX
$644M
| $38.4M | 0.98% |
2,075,545
+442,700
| +27% | +$7M |
2024 Q3
7 quarters
|
|
Similar funds
LFCM
DCM
LNC
GL
AC
FFGIM
AIM
LCM
BVF Inc's Q2 2026 Portfolio in Review
As of Q2 2026, BVF Inc held 46 positions worth $3.91B, up 25% from $3.14B the previous quarter. Its ten largest holdings account for 66% of the portfolio.
BVF Inc's Q2 2026 filing shows 5 new, 6 increased, 9 reduced and 2 closed positions. Its largest new stake was Q32 Bio: 2,350,000 shares worth $29.9M. The largest sale was Kymera Therapeutics, an estimated $140M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Miscellaneous.
- BVF Inc's largest Q2 2026 buy was Q32 Bio: 2,350,000 shares worth $29.9M.
- BVF Inc added most to Xoma in Q2 2026, an estimated $203M increase.
- BVF Inc's biggest Q2 2026 reduction was Kymera Therapeutics, cutting an estimated $140M.
- BVF Inc fully exited Compass Therapeutics in Q2 2026, selling an estimated $41.1M.
- BVF Inc's ten largest holdings make up 66% of its $3.91B portfolio in Q2 2026.
- BVF Inc opened 5 new positions and closed 2 in Q2 2026.
- BVF Inc's portfolio value rose 25% quarter-over-quarter to $3.91B.
Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.